ArticleTranslational cancer research2026
Improvement of prognosis among patients with lung adenocarcinoma through precision therapy: analysis based on The Cancer Genome Atlas.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is a malignancy with a high global incidence and cancer-related mortality rate. Over decades of development, the treatment of lung cancer has evolved from empirical approaches such as traditional chemotherapy and radiotherapy to a precision model that integrates targeted therapy, immunotherapy, and combination treatments. Through "molecular profiling and individualized treatment planning", targeted therapies focusing on biomarkers like EGFR and ALK, along with immunotherapy using programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, have become landmark achievements in precision medicine for lung cancer. Although various clinical trials have improved the prognosis of LUAD patients, their 5-year survival rate remains low, and precision therapy for lung cancer still faces multiple challenges. This study aims to improve the prognosis of LUAD patients through molecular subtype-based precision treatment. Methods: LUAD RNA-sequencing data sourced from an online database were used to screen for differentially expressed genes (DEGs). Weighted gene coexpression network analysis combined with univariate and multifactorial Cox analysis was used to identify hub prognostic genes. Based on these genes, partitioning around medoids clustering was applied to classify LUAD into two subtypes. The estimation of stromal and immune cells in malignant tumor via using expression data, immunophenoscore, and microenvironment cell populations counter algorithm was used to determine the microenvironmental purity and immune response of the two subtypes. Gene set enrichment analysis was performed to analyze the biological function. The correlation between hub gene and Results: This study delineated two distinct subtypes of LUAD, and the survival rate for patients in cluster 2 was found to be significantly superior to that of cluster 1. Additionally, patients in cluster 2 had greater immune cell infiltration, a greater microenvironmental component, and a higher rate of Conclusions: Patients in cluster 1 may benefit from anti-nucleotide repair therapies such as platinum therapy, radiotherapy, targeting of fibroblasts, and targeting of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.